Free Trial
→ Cigar Lake Flooded Again Uranium Supply Shock Repeats (From Digest Publishing) (Ad)tc pixel
NASDAQ:ARWR

Arrowhead Pharmaceuticals Q4 2026 Earnings Date & Estimates

Arrowhead Pharmaceuticals logo
$59.57 -0.33 (-0.55%)
Closing price 11/2/2026 04:00 PM Eastern
Extended Trading
$60.29 +0.72 (+1.21%)
As of 11/2/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Arrowhead Pharmaceuticals is estimated to report Q4 2026 earnings on Tuesday, November 24, 2026, after market closes. The conference call is scheduled for November 25, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q4 2026
Announcement Date
Time
After Market Closes
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Arrowhead Pharmaceuticals in Q4 2026

Arrowhead Pharmaceuticals is expected to post earnings of -$1.52 per share on revenue of $61.18 million. Arrowhead Pharmaceuticals last reported on August 4, 2026, posting -$1.36 per share and missing the -$1.23 consensus estimate. Arrowhead Pharmaceuticals has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$1.52
Expected Revenue
$61.18 million

Recent Track Record

Last Reported
Q3 2026
Last Quarter EPS
-$1.36 (Missed by -$0.13)
Last Quarter Revenue
$75.25 million
EPS Beat Rate
2 of last 8 quarters

Prepare for the Q4 2026 Call

Arrowhead Pharmaceuticals Q4 2026 Earnings FAQ

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is estimated to report Q4 2026 earnings on Tuesday, November 24, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Arrowhead Pharmaceuticals' Q4 2026 earnings conference call is scheduled for Wednesday, November 25, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Arrowhead Pharmaceuticals to post earnings of -$1.52 per share for Q4 2026.

The consensus revenue estimate for Arrowhead Pharmaceuticals is $61.18 million for Q4 2026.

Arrowhead Pharmaceuticals Earnings Headlines

Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026
November 2 at 8:00 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20261102145649/en/Arrowhead-Pharmaceuticals-to-Present-Important-Clinical-Data-at-the-American-Heart-Association-Scientific-Sessions-2026/
Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides
October 27, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261027614909/en/adults-living-with-familial-chylomicronaemia-syndrome-fcs-in-england-and-wales-have-redemplo%c2%ae-plozasiran-as-a-new-treatment-option-to-reduce-triglycerides/
Cigar Lake Flooded Again Uranium Supply Shock Repeats
In 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This past May, flooding hit the same complex again, and in July Cigar Lake went down a second time, disrupting the world's largest high-grade uranium mine. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.tc pixel
 |  Digest Publishing (Ad)
Arrowhead Pharmaceuticals And 2 Biotech Stocks To Own
October 24, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/arrowhead-pharmaceuticals-2-biotech-stocks-020934277.html
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Now Rated "Moderate Buy" by Sell-Side Analysts
October 23, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31148400
Arrowhead Pharmaceuticals (ARWR) Gets a Buy from Piper Sandler
October 17, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ARWR/pressreleases/8092249/arrowhead-pharmaceuticals-arwr-gets-a-buy-from-piper-sandler/
See More Arrowhead Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Arrowhead Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arrowhead Pharmaceuticals and other key companies, straight to your email.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is a biopharmaceutical company focused on developing medicines that silence disease-causing genes using RNA interference (RNAi). The company’s proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi-based therapies to specific tissues and reduce the production of targeted proteins.

Arrowhead’s research and development programs address a range of conditions, including cardiometabolic, pulmonary, liver, and central nervous system diseases. Its pipeline has included investigational therapies designed to treat disorders such as hypertriglyceridemia, liver disease, respiratory illness, and other conditions. The company’s products remain primarily in clinical development, and its programs have included collaborations and licensing arrangements with larger pharmaceutical companies.

Founded in 2003, Arrowhead Pharmaceuticals is headquartered in Pasadena, California. Christopher Anzalone, Ph.D., serves as the company’s president and chief executive officer. Arrowhead’s operations are primarily focused on research, clinical development, and partnerships intended to advance RNAi medicines for patients in the United States and international markets.

View Arrowhead Pharmaceuticals Profile
Earnings Tools